Learn About Primary Mediastinal B-Cell Lymphoma (PMBCL)
Condition 101 content is not available at this time, but we are continually updating the site. Please check back.
However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.
Dana-Farber Cancer Institute, Inc.
Philippe Armand is a Hematologist Oncology specialist and a Hematologist in Boston, Massachusetts. Dr. Armand and is rated as an Elite provider by MediFind in the treatment of Primary Mediastinal B-Cell Lymphoma (PMBCL). His top areas of expertise are Classical Hodgkin Lymphoma, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Graft Versus Host Disease (GvHD), and Bone Marrow Transplant. Dr. Armand is currently accepting new patients.
Dana-Farber Cancer Institute, Inc.
Caron Jacobson is an Oncologist and a Hematologist Oncology provider in Boston, Massachusetts. Dr. Jacobson has been practicing medicine for over 21 years and is rated as a Distinguished provider by MediFind in the treatment of Primary Mediastinal B-Cell Lymphoma (PMBCL). Her top areas of expertise are Non-Hodgkin Lymphoma, B-Cell Lymphoma, Follicular Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Jacobson is currently accepting new patients.
The General Hospital Corporation
Jeremy Abramson is a Hematologist Oncology specialist and a Hematologist in Boston, Massachusetts. Dr. Abramson and is rated as a Distinguished provider by MediFind in the treatment of Primary Mediastinal B-Cell Lymphoma (PMBCL). His top areas of expertise are Non-Hodgkin Lymphoma, B-Cell Lymphoma, Classical Hodgkin Lymphoma, Bone Marrow Transplant, and Tissue Biopsy. Dr. Abramson is currently accepting new patients.
Summary: This phase III trial compares the effects of nivolumab with chemo-immunotherapy versus chemo-immunotherapy alone in treating patients with newly diagnosed primary mediastinal B-cell lymphoma (PMBCL). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of cancer cells to grow and spread. Treatment for P...
Summary: To study the safety and efficacy of cord blood-derived CD19 CAR-NK cells sequential with 7x19 CAR-T in relapse / refractory B cell lymphoma